Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors
NCT05521984Phase 1Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Apr 2023
- Primary completion
- Mar 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dapagliflozin in brain tumor and solid tumor (4 arms), sponsored by Washington University School of Medicine. Primary endpoint: Number and type of adverse events experienced by participants at 4 months. Started Apr 2023; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
brain tumorsolid tumor
Beyond the preview
Go deeper on NCT05521984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05521984.